Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043810 · ClinicalTrials.gov registry record · Phase 1
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00043810: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00043810 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00043810, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Patients with Acute Myelogenous Leukemia or Myelodysplastic are able to achieve a complete remission but fail to achieve a prolonged disease-free survival. High dose chemotherapy and autologous bone marrow transplantation has been shown to be effective in this group of patients but hematopoietic recovery is slow, and infectious or bleeding complications are common. The delay in hematopoietic recover is accentuated by the use of purging techniques. This is a novel purging approach for autologous stem cell transplantation in patients with Acute Myelogenous Leukemia or Myelodysplastic syndrome to allow for rapid engraftment with a lower relapse rate therefore improving the therapeutic outcomes
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- PROCEDURE Gelonin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043810
The ClinicalTrials.gov registry entry for NCT00043810 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00043810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00043810 about?
NCT00043810 is a clinical study titled "Study of Gelonin Purging of Autologous Stem Cells for Transplantation". Patients with Acute Myelogenous Leukemia or Myelodysplastic are able to achieve a complete remission but fail to achieve a prolonged disease-free survival. High dose chemotherapy and autologous bone marrow transplantation has been shown to be effective in this group of patients but hematopoietic rec...
What is the current status of trial NCT00043810?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2002-07. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00043810?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Gelonin (PROCEDURE).
Who is sponsoring clinical trial NCT00043810?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.